	US 12,391,746 B2
	HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
Andreas Wieland, Atlanta, GA (US); and Rafi Ahmed, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Appl. No. 16/971,627
Filed by Emory University, Atlanta, GA (US)
PCT Filed Feb. 20, 2019, PCT No. PCT/US2019/018798 § 371(c)(1), (2) Date Aug. 20, 2020, PCT Pub. No. WO2019/164970, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/632,777, filed on Feb. 20, 2018.
Prior Publication US 2020/0399348 A1, Dec. 24, 2020
Int. Cl. C07K 16/08 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/46 (2025.01); C12N 5/0783 (2010.01)

CPC C07K 16/084 (2013.01) [A61K 38/2013 (2013.01); A61K 39/3955 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/46 (2025.01); C12N 5/0636 (2013.01); C07K 2317/24 (2013.01); C12N 2510/00 (2013.01)]

12 Claims

1. A chimeric antibody that specifically binds HPV16 E2 protein wherein the antibody comprises a light chain and a heavy chain,

wherein the light chain CDR1 is GYTFTSYP (SEQ ID NO: 67), CDR2 is INTNNGNP (SEQ ID NO: 68), and CDR3 is ARAGFEIYGDAFTYYGMDV (SEQ ID NO: 69); and

wherein the heavy chain CDR1 is TGDIGAYKF (SEQ ID NO: 72), CDR2 is EVSN (SEQ ID NO: 73), and CDR3 is SSYRGNTTL (SEQ ID NO: 74).